126 related articles for article (PubMed ID: 8392342)
1. Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent.
Solary E; Leteurtre F; Paull KD; Scudiero D; Hamel E; Pommier Y
Biochem Pharmacol; 1993 Jun; 45(12):2449-56. PubMed ID: 8392342
[TBL] [Abstract][Full Text] [Related]
2. Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines.
Eymin B; Solary E; Chevillard S; Dubrez L; Goldwasser F; Duchamp O; Genne P; Leteurtre F; Pommier Y
Int J Cancer; 1995 Oct; 63(2):268-75. PubMed ID: 7591216
[TBL] [Abstract][Full Text] [Related]
3. Azatoxin derivatives with potent and selective action on topoisomerase II.
Leteurtre F; Sackett DL; Madalengoitia J; Kohlhagen G; MacDonald T; Hamel E; Paull KD; Pommier Y
Biochem Pharmacol; 1995 May; 49(9):1283-90. PubMed ID: 7763310
[TBL] [Abstract][Full Text] [Related]
4. Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.
Leteurtre F; Madalengoitia J; Orr A; Guzi TJ; Lehnert E; Macdonald T; Pommier Y
Cancer Res; 1992 Aug; 52(16):4478-83. PubMed ID: 1322792
[TBL] [Abstract][Full Text] [Related]
5. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
Cline SD; Macdonald TL; Osheroff N
Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
[TBL] [Abstract][Full Text] [Related]
6. Effect of 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants.
Chang JY; Han FS; Liu SY; Wang ZQ; Lee KH; Cheng YC
Cancer Res; 1991 Apr; 51(7):1755-9. PubMed ID: 1848478
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
Leteurtre F; Kohlhagen G; Paull KD; Pommier Y
J Natl Cancer Inst; 1994 Aug; 86(16):1239-44. PubMed ID: 8040892
[TBL] [Abstract][Full Text] [Related]
8. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Activity of Ferrocenyl and Ruthenocenyl Analogues of Etoposide: Discovery of a Novel Dual Inhibitor of Topoisomerase II Activity and Tubulin Polymerization.
Chrabąszcz K; Błauż A; Gruchała M; Wachulec M; Rychlik B; Plażuk D
Chemistry; 2021 Apr; 27(20):6254-6262. PubMed ID: 33465263
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.
Yi JM; Zhang XF; Huan XJ; Song SS; Wang W; Tian QT; Sun YM; Chen Y; Ding J; Wang YQ; Yang CH; Miao ZH
Oncotarget; 2015 Apr; 6(11):8960-73. PubMed ID: 25840421
[TBL] [Abstract][Full Text] [Related]
11. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors.
Binaschi M; Capranico G; De Isabella P; Mariani M; Supino R; Tinelli S; Zunino F
Int J Cancer; 1990 Feb; 45(2):347-52. PubMed ID: 2154411
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent.
Chang JY; Hsieh HP; Pan WY; Liou JP; Bey SJ; Chen LT; Liu JF; Song JS
Biochem Pharmacol; 2003 Jun; 65(12):2009-19. PubMed ID: 12787881
[TBL] [Abstract][Full Text] [Related]
13. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
14. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888
[TBL] [Abstract][Full Text] [Related]
15. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants.
Liu SY; Hwang BD; Haruna M; Imakura Y; Lee KH; Cheng YC
Mol Pharmacol; 1989 Jul; 36(1):78-82. PubMed ID: 2546053
[TBL] [Abstract][Full Text] [Related]
16. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
17. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
Beckers T; Reissmann T; Schmidt M; Burger AM; Fiebig HH; Vanhoefer U; Pongratz H; Hufsky H; Hockemeyer J; Frieser M; Mahboobi S
Cancer Res; 2002 Jun; 62(11):3113-9. PubMed ID: 12036922
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of DNA topoisomerase II by azaelliptitoxins functionalized in the variable substituent domain.
Tepe JJ; Madalengoitia JS; Slunt KM; Werbovetz KW; Spoors PG; Macdonald TL
J Med Chem; 1996 May; 39(11):2188-96. PubMed ID: 8667362
[TBL] [Abstract][Full Text] [Related]
19. New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors.
La Regina G; Bai R; Coluccia A; Naccarato V; Famiglini V; Nalli M; Masci D; Verrico A; Rovella P; Mazzoccoli C; Da Pozzo E; Cavallini C; Martini C; Vultaggio S; Dondio G; Varasi M; Mercurio C; Hamel E; Lavia P; Silvestri R
Eur J Med Chem; 2018 May; 152():283-297. PubMed ID: 29730191
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Ling YH; Andersson BS; Nelson JA
Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
